Date: 2015-07-27
Type of information: Collaboration agreement
Compound: aminopyrazole series
Company: Drugs for Neglected Diseases initiative (DNDi) (Switzerland) Takeda Pharmaceutical (Japan)
Therapeutic area: Infectious diseases - Parasitic diseases
Type agreement: collaboration
Action mechanism:
Disease: visceral leishmaniasis
Details: * On July 27, 2015, Drugs for Neglected Diseases initiative (DNDi) and Takeda announced that they have signed an agreement to collaborate in the “Lead Optimization Program” aimed at identifying the best compound among aminopyrazole series for developing an innovative drug for the treatment of visceral leishmaniasis. DNDi and Takeda are working on the lead optimization of the aminopyrazole series. In preclinical trials,
the aminopyrazole series exhibited good antiparasitic activity, and are expected to be highly safe and effective. DNDi and Takeda consider that short-course oral administration of the drug is effective for the treatment, and therefore it is expected to be a novel drug which will be different from the existing therapeutics for visceral leishmaniasis. In addition to this collaboration agreement, DNDi and Takeda entered into partnership agreements such as the “drug discovery booster for accelerating and promoting the discovery of new drugs for treating leishmaniasis and Chagas disease.”
Financial terms: The program is being funded by Global Health Innovative Technology Fund (“GHIT”). GHIT is a public interest incorporated association and a fund for promoting the research and development of pharmaceuticals, vaccinations and the like which are needed in developing countries. GHIT Fund is investing approximately 400 million yen into DNDi for the program.
Latest news:
